Methyl-β-cyclodextrin (MCD), an established pharmacological excipient, depolymerizes the actin cytoskeleton. In this work, we investigated the effect of MCD-mediated actin depolymerization on various cellular phenotypes including traction force, cell stiffness, focal adhesions, and intracellular drug accumulation. In addition to a reduction in the contractile cellular traction, MCD acutely inhibits the maturation of focal adhesions. Alteration of contractile forces and focal adhesions affects the trypsin-mediated detachment kinetics of cells. Moreover, MCD-mediated actin depolymerization increases the intracellular accumulation of microtubule-targeting agents (MTAs) by ~50% with respect to the untreated cells. As MCD treatment enhances the intracellular concentration of drugs, we hypothesized that the MCD-sensitized cancer cells could be effectively killed by low doses of MTAs. Our results in cervical, breast, hepatocellular, prostate cancer and multidrug-resistant breast cancer cells confirmed the above hypothesis. Further, the combined use of MCD and MTAs synergistically inhibits the proliferation of tumor cells. these results indicate the potential use of MCD in combination with MtAs for cancer chemotherapy and suggest that targeting both actin and microtubules simultaneously may be useful for cancer therapy. Importantly, the results provide significant insight into the crosstalk between actin and microtubules in regulating the traction force and dynamics of cell deadhesion.
MCD treatment altered focal adhesion expression, cell stiffness, traction force and deadhesion rates in HeLa cells. MCD-treatment depolymerized the actin network and therefore, we examined the effect of MCD on various actin dependent physiological parameters like focal adhesions, cell stiffness, traction force and deadhesion kinetics in HeLa cells. The focal adhesion assembly of HeLa cells was examined by immunostaining with antibodies against initial focal adhesion protein paxillin and matured focal adhesion protein phosphorylated focal adhesion kinase protein (pFAK). The expression of paxillin and pFAK was analyzed by determining the focal adhesion area. The paxillin focal adhesion area was reduced by 56% from 0.53 ± 0.04 to 0.23 ± 0.01 µm 2 (p < 0.01) and pFAK focal adhesion kinase area reduced by 66% from 0.57 ± 0.07 to 0.23 ± 0.04 µm 2 (p < 0.01) when the cells treated with 1 mM MCD for 4 h (Fig. 2a,b ). An analysis using Atomic force microscopy (AFM) indicated that MCD treatment reduced the stiffness of HeLa cells by 50% from 4.3 ± 0.3 to 2.1 ± 0.2 kPa (p < 0.01) (Fig. 3a) . The MCD-treated cells manifest a reduction in the traction force by 65% from 367 ± 15 to 128 ± 11 Pa (p < 0.01) as measured by traction force microscopy (TFM) (Fig. 3b,c) . The rate of cell deadhesion from the substratum is a function of cell adhesion and traction force 18 . As MCD affected both cellular adhesion and traction (Figs 2a,b and 3b,c), it was interesting to study their combined effects on the deadhesion kinetics of HeLa cells. The deadhesion kinetics was studied by trypsin deadhesion assay that provided two-time constants τ 1 and τ 2 18 . τ 1 indicates the time required for an initial reduction in cell area by 50% whereas τ 2 indicates the time required for a further 50% to 75% reduction in the cell area. τ 1 depends on both cell adhesion and cellular traction whereas τ 2 depends only on the traction force 18 . We found a significant reduction in τ 1 and a modest increase in τ 2 in MCD -treated HeLa cells with respect to the controls (p < 0.01) ( Fig. 3d & Supplementary Table S2 ). (b) Microtubules were stained with β-tubulin antibody and represented in green while the nucleus is shown in blue. Vinblastine and taxol were used as positive controls (N = 3). The fluorescence intensity of both actin and microtubules were quantified using Image J (n = 100). MCD (<0.01) and LATB (<0.01) treatment significantly depolymerized the actin network.
MCD treatment strongly enhanced the antiproliferative effects of vinblastine, taxol, and crocin in several cancer cells including the multi-drug resistant ones.
As MCD treatment increased the intracellular accumulation of MTAs in HeLa cells, we investigated the effect of MCD in combination with clinically used MTAs like vinblastine and taxol against HeLa cells. To study the combined effects of MCD and MTAs, HeLa cells were initially treated with 1 mM MCD for 4 h. Then, the media with MCD was removed by washing the cells with the fresh media containing no MCD. The pre-treatment of cells with 1 mM MCD had no effect on the proliferation of HeLa cells up to 24 h. However, higher concentrations of MCD inhibited the proliferation of HeLa cells ( Supplementary Fig. S1a ). Subsequently, the cells were cultured in fresh media without and with different concentrations of either vinblastine, crocin or taxol. We found that the antiproliferative activity of vinblastine, crocin and taxol against HeLa cells is potentiated by pre-treatment with MCD. Vinblastine, taxol and crocin inhibited the proliferation of MCD-treated HeLa cells with an IC 50 value of 1.9 ± 0.2 nM, 2.7 ± 0.3 nM and 0.6 ± 0.2 µM, respectively, which are significantly (p < 0.01) lower than vinblastine, taxol and crocin alone 4.2 ± 0.1 nM, 7 ± 0.3 nM and 1.5 ± 0.1 µM, respectively ( Fig. 4a-c ). In this experiment, LAT B was also used as a positive control. HeLa cells were pre-treated with 200 nM LAT B for 4 h. Upon pre-treatment with LAT B, vinblastine and taxol inhibited HeLa cell proliferation with an IC 50 value of 2.3 ± 0.2 (p < 0.01) and 3.5 ± 0.2 (p < 0.01) nM, respectively indicating that the pre-treatment with LAT B could sensitize the cells towards the anti-microtubule agents. Further, we examined whether the pre-treatment with MCD could increase the antiproliferative effects of vinblastine and taxol in several other cancer cell lines. The antiproliferative effects of vinblastine and taxol were strongly enhanced in the liver (Huh 7) ( Supplementary Fig S2a,b) , breast (MCF-7) ( Supplementary Fig. S2c,d ), prostate (PC3) ( Supplementary Fig. S2e ,f) cancer cells when the cells were pre-treated with MCD. The augmented anti-proliferative effects of vinblastine and taxol on MCD sensitized several cancer cells encouraged us to investigate the potential of this drug combination on multi-drug resistant mouse breast mammary carcinoma (EMT/ AR1) cells. The IC 50 value of vinblastine was reduced from 3.7 ± 0.6 µM to 1 ± 0.05 µM (p < 0.01) and that of taxol from 1.2 ± 0.03 µM to 0.5 ± 0.02 µM (p < 0.01) indicating that MCD can sensitize drug-resistant cells towards MTAs ( Supplementary Fig S2g,h) . Supplementary Table S3 summarizes the IC 50 values of vinblastine and taxol on control and MCD treated several cancer cell types. the anti-mitotic effect of vinblastine on cell cycle arrest was enhanced by MCD treatment. The antiproliferative effect of vinblastine and taxol was found to increase upon pre-treatment of cells with 1 mM MCD for 4 h (Fig. 4 ). As vinblastine is known to block the HeLa cells at mitosis 24 , it was important to investigate the effect of vinblastine on the cell cycle of MCD-treated HeLa cells. We found that prior treatment with MCD increased vinblastine (5 nM) mediated G2/M block from 37 ± 2% to 60 ± 4% (p < 0.01) ( Fig. 5a,b ). As the cells are blocked in the G2-M phase, we expected a significant reduction in the number of cells in S phase. BrdU (5-Bromo-2′-deoxyuridine) assay, which estimates the percentage of cells in the S phase of the cell cycle 25 , confirmed the prediction. The percentage of cells in the S phase was reduced from 66 ± 0.7% in control to 35 ± 2.9% after 8 h of vinblastine treatment. When the cells were incubated with MCD for 4 h prior to the addition of vinblastine, the percentage of cells in the S phase was further reduced to be 18 ± 1.6% (p < 0.01) ( Fig. 5c,d ).
MCD treatment augmented the effect of vinblastine, taxol, crocin on both interphase and mitotic microtubules. MCD treatment had no discernible effect on the microtubules in HeLa cells (Fig. 1b).
However, prior treatment with 1 mM MCD for 4 h was found to enhance the effects of vinblastine, crocin, and taxol on microtubules of both interphase ( Fig. 6a ) and mitotic HeLa cells (Fig. 6b ). The fluorescence intensities are summarized in Supplementary Table S1 . For example, while 5 nM vinblastine treatment alone reduced the www.nature.com/scientificreports www.nature.com/scientificreports/ fluorescence intensity of microtubules by 43% of the control, pre-treatment with MCD reduced it further to 62%. Similarly, the effects of crocin and taxol on microtubules were found to be potentiated upon MCD treatment.
the interplay of actin and microtubule assembly on the traction force and adhesion dynamics of HeLa cells. We wanted to comprehend the combined effects of MCD and MTA on cellular contractility
and cell deadhesion kinetics, by TFM and trypsin deadhesion assay, respectively. As shown earlier (Fig. 3b ,c), MCD treatment reduced the traction force from 367 ± 25 Pa to 128 ± 8 with respect to the control. However, 5 nM vinblastine treatment increased the traction force to 524 ± 24 Pa. A prior 4 h MCD treatment followed by vinblastine showed somewhat intermediate traction force as 292 ± 25 Pa. Similarly, at 7 nm taxol treatment reduced the traction force to 214 ± 13 Pa and a combination with MCD is 198 ± 15 Pa (Fig. 7a,b ). The effects of vinblastine and taxol on the detachment kinetics of the cell deadhesion were analyzed by determining the τ 1 and τ 2 values ( Supplementary Table S2 ) as described earlier. Neither vinblastine nor taxol treatment significantly altered the τ 1 values of HeLa cells. However, the τ 2 values for vinblastine and taxol-treated cells indicate faster and slower deadhesion, respectively with respect to the control. MCD nullified the effect of vinblastine resulting in intermediate τ 1 and τ 2 values whereas MCD and taxol acted in synergy to increase both τ 1 and τ 2 values. (Fig. 7c ).
MCD and vinblastine exert a synergistic anti-proliferative effect on HeLa cells. The
MCD-sensitized cancer cells exhibited a significantly higher inhibition of cell proliferation against vinblastine and taxol as compared to the control cells. Therefore, we evaluated the inhibitory effect of vinblastine on HeLa cell proliferation when used in combination with either 0.25 or 1 mM MCD for 24 h. The IC 50 value of vinblastine was determined to be 0.7 ± 0.1 and 2.1 ± 0.2 nM in the presence of 1 and 0.25 mM MCD, respectively (Fig. 8a) . The median dose of vinblastine and MCD was determined to be 4.5 nM and 3.7 mM, respectively (Fig. 8b,c) . Vinblastine in combination with 1 and 0.25 mM MCD was found to synergistically inhibit the proliferation of HeLa cells with a combination index of 0.43 and 0.55, respectively 26, 27 .
Discussion
Consistent with the earlier reports 10, 11 , MCD treatment was found to disassemble the actin network. In this work, we showed that MCD treated HeLa cells manifest a decrease in the expression of both early and mature focal adhesions proteins such as paxillin and pFAK, respectively. Using traction force microscopy, MCD-treatment was found to reduce both the traction force and cell stiffness. MCD treatment also enhanced the permeability www.nature.com/scientificreports www.nature.com/scientificreports/ of the cell membrane and thereby allows higher uptake of small molecules such as BODIPY vinblastine, crocin, and curcumin. LAT B and MCD enhanced the intracellular accumulation of BODIPY vinblastine by 35 and 53%, respectively indicating that the depolymerization of actin network may be the cause for the enhanced intracellular drug accumulation. However, the difference in the level of drug uptake also suggests that an additional mechanism may exist for MCD to further enhance the membrane permeability.
The traction force of a cell is a resultant of actomyosin generated contractile force and counteracting microtubules 28 . Perturbations to any of these cytoskeletal elements are expected to change the resultant traction force 29, 30 . This work provides evidence of variations in the traction force and deadhesion kinetics of the cell when both actin and microtubules were perturbed simultaneously. We observed that the depolymerization of actin overrides the effect of the microtubule perturbation on the traction force. Vinblastine treatment depolymerized microtubules and increased the traction force. However, a 4 h prior MCD treatment, which disassembled the actin, almost nullified the vinblastine-induced increase in the traction force. This is because the actomyosin complex is responsible for the generation of cellular traction and microtubules acts as a counteracting stabilizer to this force. The de-adhesion kinetics of a cell upon trypsin treatment is a combined function of cellular traction and focal adhesions. While traction facilitates the deadhesion process, strong focal attachments decelerate it 18, 31 . τ 1 is dependent on the combined effect of focal adhesions and traction while τ 2 estimates the contractile force alone 18 . Upon MCD treatment, the cells are de-adhering faster (τ 1 ) as compared to controls due to the effect of weaker focal adhesions while the τ 2 values increased due to the reduction in the traction force. However, vinblastine and taxol-treated cells did not show a significant change in τ 1 values with respect to the control. The unaltered τ 1 values suggest that focal adhesions are not altered by the administration of a low dosage of tubulin inhibitors though literature suggests that higher doses of the tubulin inhibitors modulate the expression of focal adhesion www.nature.com/scientificreports www.nature.com/scientificreports/ proteins 32, 33 . The effect of altered traction force upon vinblastine and taxol treatment can be seen from the varying τ 2 values with respect to control. The increased and decreased traction force in case of vinblastine and taxol treatment, respectively, had an opposite effect on the τ 2 values. Further, simultaneous perturbation of the actin and microtubule networks by MCD and MTAs manifested intermediate τ 1 values. This can be due to the combined effect of reduced focal adhesion by MCD and unaltered focal adhesion upon treatment with MTAs. MCD's action in terms of cellular traction is opposite to vinblastine and in combination, they enhance the τ 2 values as compared to both control and vinblastine alone. This phenomenon further confirms that actomyosin generated contractile force supersedes the counter stabilizing action of microtubules. Further, taxol and MCD together worked synergistically to enhance the τ 2 values significantly because both acted compositely to reduce the traction force. This study illustrates the interplay between actin and microtubules on traction force and deadhesion kinetics of the cells and provides a deeper insight towards understanding the force dynamics played by the cytoskeletal elements of the cell. www.nature.com/scientificreports www.nature.com/scientificreports/ MCD has been used to enhance the bioavailability and solubility of several drug candidates 1, 4 . In this work, we show that MCD sensitized multiple cancer cells such as cervical, breast, liver, and prostate cancer showed a potentiated response to MTAs such as vinblastine, taxol, and crocin 22, 34 . Further, to show that this augmented cell inhibition response was due to the depolymerizing effect of MCD on the actin network, LAT B a well-known inhibitor of actin polymerization was used as a positive control. A very low dosage of LAT B enhanced the antiproliferative efficacy of vinblastine and taxol. This confirms that MCD mediated actin depolymerization synergistically acts with MTAs to increase their efficacy in cell inhibition. Additionally, we show that the multi-drug resistant breast cancer cell line EMT/AR1 also show promising response when pre-treated with MCD. Actin targeted anti-proliferative drugs are highly toxic and therefore are not used for cancer chemotherapy 35, 36 . As reported earlier, we have also found that MCD at higher doses leads to cell death 37, 38 . In this work, we used the concentration of MCD which didn't perturb the cell proliferation rather increases the intracellular drug accumulation of MTAs by actin depolymerization. Additionally, we found that simultaneous use of low concentration of MCD with vinblastine synergistically inhibits the proliferation of cancer cells. This study indicates that the perturbation of actin network by MCD along with microtubule depolymerization by MTAs provides an effective drug administration strategy to cancer patients who are struggling with drug resistance.
The present study indicates that MCD-induced actin depolymerization increases plasma membrane permeability, which allows the passage of more MTAs inside the cells and thereby increases their physiological concentrations. This sort of combination enables us to understand the crosstalk between microtubules and actin filaments and their inter-dependent roles in several physical parameters such as stiffness, adhesion and traction force of a cell. The results also suggest that devising a method to manipulate both actin and microtubules can be effective in devising new strategies to cancer therapeutic regimen. BrdU assay. Cells (1 × 10 5 cells ml −1 ) were seeded on glass coverslips for 16 h and then, the cells were treated with 5 nM vinblastine for 8 h. In the case of MCD treatment, cells were first treated with 1 mM MCD for 4 h and then, the cells treated with 5 nM vinblastine for 8 h. After the drug treatment, BrdU reagent (Roche Diagnostics) was added in 1:1000 (v/v) ratio in media and incubated for 4 h at 37 °C with 5% CO 2 . Cells were processed for immunofluorescence 45 . Cells were incubated with anti-BrdU antibody (DSHB, University of Iowa) at 1:200 dilution in 1.5% BSA overnight at 4 °C followed by incubation with secondary antibody goat anti-mouse Alexa flour 568 at 1: 400 dilution for 3 h. Cell nuclei were stained with Hoechst 33258 at 1:10000 dilution. Immunofluorescence images were acquired and the percentage of BrdU positive cells were counted manually using Image J software. www.nature.com/scientificreports www.nature.com/scientificreports/ Immunofluorescence microscopy for microtubule, actin and focal adhesion staining. Cells were seeded at a density of 0.5 × 10 5 cells ml −1 on glass coverslips. After 16 h they were treated with 1 mM MCD for 4 h and consequently with the drug for 8 h. After the incubation, cells were processed for immunofluorescence staining using specific antibodies as described earlier 40, 46 . Cells were incubated with anti-mouse β-tubulin (1:300) antibody, anti-mouse paxillin antibody (1: 200) and anti-mouse pFAK antibody (1:200) for early and mature focal adhesion protein, respectively overnight at 4 °C followed by labeling with FITC conjugated anti-mouse secondary IgG (1:400) for microtubules and Alexa Flour 564 rabbit anti-mouse for focal adhesions for 1 h at room temperature. Actin was stained using Alexa flour 488 Phalloidin. Hoechst 33258 (1:10000) was used to stain the nucleus. Images were captured using a laser scanning confocal microscope (Zeiss 780) and processed using Zeiss ZEN software. The size of focal adhesions and the fluorescence intensity of actin and microtubules were determined using ImageJ software. A total of 100 cells were scored in each case.
Methods
Drug accumulation assay. Cells were seeded in T 25 flasks and allowed to reach 50% confluency. HeLa cells were treated with 1 mM MCD for 4 h. The media with MCD was then carefully removed and then cells were subsequently treated with a fresh media containing with either 5 nM BODIPY vinblastine for 6 h or 1 μM crocin and 5 μM curcumin for 24 h. Cells were trypsinized using (0.05%) trypsin (HiMedia, India) containing (0.02%) EDTA (Sigma -Aldrich) followed by two PBS wash containing soybean trypsin inhibitor (HiMedia, India). The cell pellet was suspended in fresh 1 ml PBS and the cells were counted by hemocytometer. An equal number of cells for each condition was lysed by incubating in lysis buffer (150 mM NaCl, 0.1% Triton X-100, 50 mM Tris-HCl pH 8.0) for 1 h on ice with 10 s vortex every 10 min. The cell lysate was centrifuged at 19000 rpm for 20 minutes at 4 °C. The BODIPY vinblastine fluorescence of the supernatant was monitored at 513 nm using 485 as the excitation wavelength. The absorbance of the supernatant comprising of the cytosolic extract was taken at 425 and 440 nm for crocin and curcumin, respectively. The intracellular drug concentration for crocin and curcumin was determined from the absorbance. trypsin cell deadhesion assay. Cell deadhesion study was performed using time-lapse microscopy as described 18, 47 . Cells were seeded (0.5 × 10 5 cells ml −1 ) density on glass coverslips. Following drug treatment, they were observed under Live-cell Imaging microscopy (EVOS FL, Life technologies, Invitrogen). Trypsin (0.05%) was added and images were captured at an interval of 25 s until the cells are completely de-adhered. Cell area quantification was done using ImageJ software and time constants were calculated using the Boltzmann linear regression curve fit on GraphPad Prism software. traction force microscopy. Traction force microscopy was done as described earlier 47, 45 . A 5 kPa gel was made using 40% (w/v) acrylamide and 2% (w/v) bis-acrylamide stock, (1:1000) 10% Ammonium persulfate, 10% and (1:10000) Tetramethylethylenediamine (TEMED) on 22 × 22 mm 2 coverslips. For making TFM gels, 25 µl of gel solution was mixed with red fluorescent beads of 1 µm (Fluka) in 1:50 to dilution with APS and TEMED solution and placed on the hydrophobic coverslip. The pre-casted solidified 5 kPa gel was placed on the top of it. After solidification, gels were treated with sulpho-sanpah (Pierce; Thermo Scientific) and incubated with collagen type I (50 μg ml −1 ) (Advanced Biomatrix) overnight. Later (0.5 × 10 5 cells ml −1 ) cells were seeded on it. After 16 h they were treated with 1 mM MCD for 4 h and then with 5 nM vinblastine / 7 nM taxol for 8 h. Imaging was done using phase contrast microscopy (EVOS FL, Life technologies, Invitrogen). Both fluorescent bead and phase cell images were taken for live cells. Following that, cells were lysed using 1% Triton X-100 and images were taken for the fluorescent beads without disturbing the gels. The bead displacement and traction forces were calculated using the code from 48 in MATLAB (MathWorks).
Atomic force microscopy. Cells were seeded (0.5 × 10 5 cells ml −1 ) density on glass coverslips. Following 1 mM MCD treatment for 4 h, atomic force measurements are taken with TR400PB silicon nitride pyramidal tip probe on MFP-3D (Asylum Research) under contact mode force. The spring constant of the cantilever was 0.02 Nm −1 and frequency is 10 kHz. The force curves were then fitted with the Hertz model provided within the software from Asylum research.
Determination of combination index. HeLa cells were incubated with either 1 or 0.25 mM MCD and different concentrations of vinblastine for 24 h. The combination index (CI) was determined by the Chou and Talalay method 26 to know whether the combination of MCD and vinblastine could inhibit HeLa cell proliferation synergistically or additively 27, 34 . A CI of < 1 suggests a synergistic combination.
The following equation was used to determine the combination index 26 . 
